CHALLENGES AND ADVANCES IN METASTATIC NON-SMALL CELL LUNG CANCER WITH EGFR MUTATION

Castro-Mollo M.; Ruiz R.; Roque K.; Mas L. · Revista de la Facultad de Medicina Humana (2024) · DOI: 10.25176/rfmh.v24i2.6441

Resumen

Introduction: Tyrosine kinase inhibitors have dramatically changed the clinical outcomes for patients with advanced non-small cell lung cancer with epidermal growth factor receptor mutations. However, there are still challenges in the management of patients with this mutation in a metastatic setting, such as intrinsic and acquired resistance to tyrosine kinase inhibitors. We will discuss the latest advances and new strategies in first-line treatment, osimertinib resistance, and exon 20 mutation treatment.

Instituciones: Universidad Peruana Cayetano Heredia; Universidad de San Martín de Porres